staccato fentanyl (AZ-003) / Ferrer International, Lee's Pharm - LARVOL DELTA

A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Lee's Pharmaceutical Limited | Initiation date: Dec 2025 ➔ Aug 2025

Trial initiation date • Oncology • Solid Tumor

A Study of Inhaled Fentanyl Aerosol in Chinese Patients With Malignant Tumors (clinicaltrials.gov) - P1 | N=100 | Not yet recruiting | Sponsor: Lee's Pharmaceutical Limited

New P1 trial • Oncology • Solid Tumor

Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial. (PubMed, BMC Palliat Care) - P1/2, P2 | "Treatment with fentanyl inhalant was shown to be a promising therapeutic option for BTcP, with significant pain relief starting very soon after dosing. Confirmation of effectiveness requires a larger phase III trial."

Clinical • Journal • Oncology • Pain

Inhaled fentanyl aerosol through a drug-device combination for breakthrough cancer pain: A multicenter, randomized, double-blind, placebo-controlled trial. (ASCO 2024) - P2 | "Fentanyl inhalant is safe, effective, and well-tolerated for managing BTcP. It provides a non-invasive route for systemic drug delivery and can be self-administered or given by family caregivers as personalized and regular pain management. Clinical trial information: NCT05531422."

Clinical • Oncology • Pain

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP (clinicaltrials.gov) - P2 | N=60 | Completed | Sponsor: Lee's Pharmaceutical Limited | Not yet recruiting ➔ Completed

Trial completion • Oncology • Pain

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP (clinicaltrials.gov) - P2 | N=60 | Not yet recruiting | Sponsor: Lee's Pharmaceutical Limited

New P2 trial • Pain

14-3-3σ and Its Modulators in Cancer. (PubMed, Pharmaceuticals (Basel)) - "This includes the new fusicoccanes stabilizers (FC-NAc, DP-005), fragment stabilizers (TCF521-123, TCF521-129, AZ-003, AZ-008), phosphate-based inhibitors (IMP, PLP), peptide inhibitors (2a-d), as well as inhibitors from natural sources (85531185, 95911592). Additionally, this review will also include the discussions of the recent efforts by a different group of researchers for understanding the binding mechanisms of existing 14-3-3σ PPI modulators. The strategies and state-of-the-art techniques applied by various group of researchers in the discovery of a different chemical class of 14-3-3σ modulators for cancer are also briefly discussed in this review, which can be used as a guide in the development of new 14-3-3σ modulators in the near future."

Journal • Review • Oncology • TCF21